OptiNose (NASDAQ:OPTN) Stock Price Up 7.7%

OptiNose Inc (NASDAQ:OPTN)’s share price rose 7.7% on Wednesday . The stock traded as high as $11.66 and last traded at $11.41, approximately 433,000 shares changed hands during trading. An increase of 123% from the average daily volume of 194,453 shares. The stock had previously closed at $10.59.

OPTN has been the topic of a number of analyst reports. BMO Capital Markets dropped their target price on OptiNose from $26.00 to $24.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Royal Bank of Canada set a $20.00 price target on OptiNose and gave the stock a “buy” rating in a research note on Monday, August 12th. Zacks Investment Research raised OptiNose from a “sell” rating to a “hold” rating in a report on Saturday. Finally, ValuEngine lowered OptiNose from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $21.50.

The company has a quick ratio of 4.66, a current ratio of 4.81 and a debt-to-equity ratio of 1.67. The business’s 50 day moving average is $8.13 and its 200-day moving average is $7.46. The firm has a market cap of $432.86 million, a P/E ratio of -4.26 and a beta of 0.63.

OptiNose (NASDAQ:OPTN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.69). The firm had revenue of $12.40 million for the quarter, compared to the consensus estimate of $8.56 million. OptiNose had a negative net margin of 419.37% and a negative return on equity of 137.60%. As a group, equities analysts predict that OptiNose Inc will post -2.73 earnings per share for the current year.

A number of large investors have recently bought and sold shares of OPTN. Northern Trust Corp increased its holdings in OptiNose by 0.8% in the second quarter. Northern Trust Corp now owns 227,704 shares of the company’s stock valued at $1,611,000 after buying an additional 1,797 shares during the last quarter. Bank of America Corp DE grew its position in shares of OptiNose by 8.1% in the 2nd quarter. Bank of America Corp DE now owns 105,689 shares of the company’s stock worth $748,000 after acquiring an additional 7,944 shares in the last quarter. Swiss National Bank grew its position in shares of OptiNose by 36.4% in the 2nd quarter. Swiss National Bank now owns 30,700 shares of the company’s stock worth $217,000 after acquiring an additional 8,200 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of OptiNose by 6.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 155,873 shares of the company’s stock valued at $1,104,000 after acquiring an additional 9,516 shares during the last quarter. Finally, UBS Asset Management Americas Inc. bought a new stake in shares of OptiNose in the 2nd quarter valued at approximately $72,000. Institutional investors and hedge funds own 67.72% of the company’s stock.

About OptiNose (NASDAQ:OPTN)

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Further Reading: How Do I Invest in Dividend Stocks

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.